Two Sigma Advisers LP Makes New Investment in Moderna, Inc. (NASDAQ:MRNA)

Two Sigma Advisers LP purchased a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 356,500 shares of the company's stock, valued at approximately $23,825,000. Two Sigma Advisers LP owned 0.09% of Moderna as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Simplicity Wealth LLC grew its holdings in shares of Moderna by 31.6% during the second quarter. Simplicity Wealth LLC now owns 4,838 shares of the company's stock worth $575,000 after purchasing an additional 1,161 shares during the last quarter. Czech National Bank raised its holdings in Moderna by 8.9% in the 2nd quarter. Czech National Bank now owns 63,536 shares of the company's stock valued at $7,545,000 after acquiring an additional 5,170 shares in the last quarter. Granite Bay Wealth Management LLC acquired a new position in shares of Moderna during the 2nd quarter worth $524,000. Sequoia Financial Advisors LLC grew its position in Moderna by 7.1% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 8,722 shares of the company's stock worth $1,036,000 after acquiring an additional 575 shares during the last quarter. Finally, Wedmont Private Capital grew its position in shares of Moderna by 48.4% in the 2nd quarter. Wedmont Private Capital now owns 3,075 shares of the company's stock valued at $373,000 after buying an additional 1,003 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research reports. UBS Group reduced their price objective on Moderna from $140.00 to $108.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Bank of America lowered their price objective on Moderna from $130.00 to $110.00 and set a "neutral" rating on the stock in a research report on Friday, September 13th. Berenberg Bank assumed coverage on Moderna in a research report on Tuesday, November 19th. They set a "hold" rating and a $42.00 price target on the stock. The Goldman Sachs Group decreased their price objective on Moderna from $178.00 to $139.00 and set a "buy" rating on the stock in a report on Monday, September 16th. Finally, Jefferies Financial Group cut their target price on Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research note on Tuesday, October 15th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $83.33.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company's stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,850 shares of company stock worth $134,560. Insiders own 15.70% of the company's stock.

Moderna Trading Up 3.5 %

Shares of NASDAQ MRNA traded up $1.50 during midday trading on Friday, reaching $44.44. 8,735,641 shares of the stock were exchanged, compared to its average volume of 10,344,880. Moderna, Inc. has a 52-week low of $35.80 and a 52-week high of $170.47. The stock has a 50 day moving average price of $50.27 and a 200-day moving average price of $87.86. The company has a market capitalization of $17.10 billion, a P/E ratio of -7.64 and a beta of 1.58. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analysts' expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.39) earnings per share. Equities research analysts expect that Moderna, Inc. will post -9.32 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.